Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10,438.00 GBX | +0.44% |
|
-3.64% | -0.42% |
06-02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
06-02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
Projected Income Statement: AstraZeneca PLC
Annual
Quarterly
Halfyear
Annual
Quarterly
Halfyear
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 57,830 | 61,182 | 64,582 |
Change | - | 40.58% | 18.53% | 3.29% | 18.03% | 6.95% | 5.8% | 5.56% |
EBITDA 1 | 8,311 | 7,586 | 9,237 | 13,580 | 16,691 | 19,647 | 22,555 | 24,743 |
Change | - | -8.72% | 21.76% | 47.02% | 22.91% | 17.71% | 14.8% | 9.7% |
EBIT 1 | 7,340 | 9,928 | 13,350 | 14,534 | 16,928 | 18,538 | 20,755 | 22,887 |
Change | - | 35.26% | 34.47% | 8.87% | 16.47% | 9.51% | 11.96% | 10.27% |
Interest Paid 1 | -782 | -862 | -1,251 | -1,282 | -1,284 | -1,120 | -953.2 | -940.7 |
Earnings before Tax (EBT) 1 | 3,916 | -265 | 2,501 | 6,899 | 8,691 | 12,702 | 15,295 | 17,211 |
Change | - | -106.77% | 1,043.77% | 175.85% | 25.97% | 46.15% | 20.42% | 12.52% |
Net income 1 | 3,196 | 112 | 3,288 | 5,961 | 7,035 | 9,919 | 11,947 | 13,392 |
Change | - | -96.5% | 2,835.71% | 81.3% | 18.02% | 41% | 20.44% | 12.1% |
Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: AstraZeneca PLC
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 11,867 | 24,383 | 22,923 | 22,510 | 24,570 | 20,263 | 12,878 | 3,070 |
Change | - | 105.47% | -5.99% | -1.8% | 9.15% | -17.53% | -36.45% | -76.16% |
Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | - | - | - |
1USD in Million
Estimates
Cash Flow Forecast: AstraZeneca PLC
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 961 | 1,091 | 1,091 | 1,361 | 1,924 | 2,472 | 2,462 | 2,423 |
Change | - | 13.53% | 0% | 24.75% | 41.37% | 28.46% | -0.39% | -1.58% |
Free Cash Flow (FCF) 1 | 3,838 | 4,872 | 8,717 | 8,984 | 9,937 | 7,603 | 12,703 | 14,335 |
Change | - | 26.94% | 78.92% | 3.06% | 10.61% | -23.48% | 67.07% | 12.85% |
Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: AstraZeneca PLC
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
EBITDA Margin (%) | 31.22% | 20.27% | 20.83% | 29.64% | 30.87% | 33.97% | 36.86% | 38.31% |
EBIT Margin (%) | 27.58% | 26.53% | 30.1% | 31.73% | 31.31% | 32.06% | 33.92% | 35.44% |
EBT Margin (%) | 14.71% | -0.71% | 5.64% | 15.06% | 16.07% | 21.96% | 25% | 26.65% |
Net margin (%) | 12.01% | 0.3% | 7.41% | 13.01% | 13.01% | 17.15% | 19.53% | 20.74% |
FCF margin (%) | 14.42% | 13.02% | 19.65% | 19.61% | 18.38% | 13.15% | 20.76% | 22.2% |
FCF / Net Income (%) | 120.09% | 4,350% | 265.12% | 150.71% | 141.25% | 76.65% | 106.33% | 107.04% |
Profitability | ||||||||
ROA | 4.99% | 8.77% | 3.26% | 11.48% | 12.51% | 10.81% | 11.85% | 12.68% |
ROE | 36.72% | 27.51% | 27.23% | 29.77% | 32.11% | 31.78% | 32% | 31.59% |
Financial Health | ||||||||
Leverage (Debt/EBITDA) | 1.43x | 3.21x | 2.48x | 1.66x | 1.47x | 1.03x | 0.57x | 0.12x |
Debt / Free cash flow | 3.09x | 5x | 2.63x | 2.51x | 2.47x | 2.67x | 1.01x | 0.21x |
Capital Intensity | ||||||||
CAPEX / Current Assets (%) | 3.61% | 2.92% | 2.46% | 2.97% | 3.56% | 4.27% | 4.02% | 3.75% |
CAPEX / EBITDA (%) | 11.56% | 14.38% | 11.81% | 10.02% | 11.53% | 12.58% | 10.92% | 9.79% |
CAPEX / FCF (%) | 25.04% | 22.39% | 12.52% | 15.15% | 19.36% | 32.51% | 19.38% | 16.9% |
Items per share | ||||||||
Cash flow per share 1 | 3.655 | 4.179 | 6.287 | 6.623 | 7.589 | 10.43 | 11.52 | 13.16 |
Change | - | 14.33% | 50.46% | 5.34% | 14.58% | 37.48% | 10.39% | 14.27% |
Dividend per Share 1 | 2.8 | 2.87 | 2.9 | 2.9 | 3.1 | 3.213 | 3.376 | 3.535 |
Change | - | 2.5% | 1.05% | 0% | 6.9% | 3.64% | 5.07% | 4.72% |
Book Value Per Share 1 | 11.91 | 27.69 | 23.93 | 25.06 | 26.09 | 28.89 | 33.14 | 38.54 |
Change | - | 132.51% | -13.6% | 4.74% | 4.13% | 10.72% | 14.72% | 16.28% |
EPS 1 | 2.44 | 0.08 | 2.11 | 3.81 | 4.5 | 6.384 | 7.694 | 8.775 |
Change | - | -96.72% | 2,537.5% | 80.57% | 18.11% | 41.86% | 20.52% | 14.05% |
Nbr of stocks (in thousands) | 1,312,660 | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,658 | 1,550,658 | 1,550,658 |
Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | - | - | - |
1USD
Estimates
2025 * | 2026 * | |
---|---|---|
P/E ratio | 21.9x | 18.2x |
PBR | 4.84x | 4.22x |
EV / Sales | 4.1x | 3.76x |
Yield | 2.3% | 2.41% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Sell
Buy

Mean consensus
BUY
Number of Analysts
20
Last Close Price
139.98USD
Average target price
179.12USD
Spread / Average Target
+27.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- Financials AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition